JP2010514455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514455A5 JP2010514455A5 JP2009544412A JP2009544412A JP2010514455A5 JP 2010514455 A5 JP2010514455 A5 JP 2010514455A5 JP 2009544412 A JP2009544412 A JP 2009544412A JP 2009544412 A JP2009544412 A JP 2009544412A JP 2010514455 A5 JP2010514455 A5 JP 2010514455A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphocytes
- composition
- antigen
- composition according
- cytotoxic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 210000004698 lymphocyte Anatomy 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 4
- 230000035131 DNA demethylation Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 210000004443 dendritic cell Anatomy 0.000 claims 3
- 230000006195 histone acetylation Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000003698 anagen phase Effects 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 230000006197 histone deacetylation Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0700058.1 | 2007-01-03 | ||
| GBGB0700058.1A GB0700058D0 (en) | 2007-01-03 | 2007-01-03 | Anti-tumor vaccine based on normal cells |
| PCT/EP2008/050050 WO2008081035A1 (en) | 2007-01-03 | 2008-01-03 | Anti-tumor vaccine derived from normal chemically modified cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514455A JP2010514455A (ja) | 2010-05-06 |
| JP2010514455A5 true JP2010514455A5 (cg-RX-API-DMAC7.html) | 2012-10-25 |
| JP5452231B2 JP5452231B2 (ja) | 2014-03-26 |
Family
ID=37759205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544412A Expired - Fee Related JP5452231B2 (ja) | 2007-01-03 | 2008-01-03 | 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10023839B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2102331B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5452231B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE522600T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008203730B2 (cg-RX-API-DMAC7.html) |
| CY (1) | CY1112668T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2102331T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2372713T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0700058D0 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20110899T1 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2102331T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2102331E (cg-RX-API-DMAC7.html) |
| SI (1) | SI2102331T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008081035A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA011421B1 (ru) * | 2008-08-26 | 2009-02-27 | Петр Генриевич ЛОХОВ | Способ получения противоопухолевой вакцины |
| US8467973B2 (en) | 2009-07-28 | 2013-06-18 | Promising Future, Llc | Pairing processes for preparing alloreactive cytotoxic T cells |
| US8666674B2 (en) | 2009-07-28 | 2014-03-04 | Promising Future, Llc | Pairing processes for preparing reactive cytotoxic T cells |
| US9211321B2 (en) | 2009-10-27 | 2015-12-15 | Immunicum Ab | Method for proliferation of antigen-specific T cells |
| GB201013443D0 (en) | 2010-08-11 | 2010-09-22 | Cytovac As | Compositions and methods for producing dendritic cells |
| US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| EA201792642A1 (ru) | 2015-05-28 | 2018-10-31 | Кайт Фарма, Инк. | Способы диагностики для т-клеточной терапии |
| IL312426B1 (en) | 2015-05-28 | 2025-10-01 | Kite Pharma Inc | Methods for training patients for T-cell therapy |
| TW202521141A (zh) | 2015-10-20 | 2025-06-01 | 美商凱特製藥公司 | 製備用於ｔ細胞治療之ｔ細胞的方法 |
| UA128781C2 (uk) | 2016-04-01 | 2024-10-23 | Кайт Фарма, Інк. | Т-клітина, спосіб її отримання та застосування |
| CU20180121A7 (es) | 2016-04-01 | 2019-05-03 | Kite Pharma Inc | Receptores de antígenos quiméricos y células t |
| KR102522622B1 (ko) | 2016-04-01 | 2023-04-18 | 카이트 파마 인코포레이티드 | Bcma 결합 분자 및 그의 사용 방법 |
| WO2018152181A1 (en) | 2017-02-14 | 2018-08-23 | Kite Pharma, Inc. | Cd70 binding molecules and methods of use thereof |
| US20180280437A1 (en) | 2017-03-13 | 2018-10-04 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| BR112019020214A2 (pt) | 2017-04-01 | 2020-04-22 | Avm Biotechnology Llc | substituição do pré-condicionamento citotóxico antes da imunoterapia celular |
| CN110494158A (zh) | 2017-04-03 | 2019-11-22 | 凯德药业股份有限公司 | 使用包含优化的多功能t细胞的嵌合受体t细胞进行治疗 |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| CN110662831A (zh) | 2017-05-26 | 2020-01-07 | 凯德药业股份有限公司 | 制备和使用胚胎间充质祖细胞的方法 |
| SG11202002327PA (en) | 2017-09-15 | 2020-04-29 | Kite Pharma Inc | Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking |
| WO2019060695A1 (en) | 2017-09-22 | 2019-03-28 | Kite Pharma, Inc. | CHIMERIC POLYPEPTIDES AND USES THEREOF |
| WO2019079564A1 (en) | 2017-10-18 | 2019-04-25 | Kite Pharma, Inc. | METHODS OF DELIVERY OF CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY |
| US11390655B2 (en) | 2017-11-16 | 2022-07-19 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| TW201932593A (zh) | 2018-01-15 | 2019-08-16 | 美商輝瑞大藥廠 | 合併投與嵌合抗原受體之免疫療法與4-1bb促效劑的方法 |
| US12338459B2 (en) | 2018-02-02 | 2025-06-24 | Arizona Board Of Regents On Behalf Of Arizona State University | DNA-chimeric antigen receptor T cells for immunotherapy |
| KR102618231B1 (ko) | 2018-02-16 | 2023-12-28 | 카이트 파마 인코포레이티드 | 변형된 만능성 줄기 세포, 및 제조 및 사용 방법 |
| AU2019252944B2 (en) | 2018-04-12 | 2022-12-08 | Kite Pharma, Inc. | Chimeric receptor T cell treatment using characteristics of the tumor microenvironment |
| KR102734592B1 (ko) | 2018-06-01 | 2024-11-27 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 t 세포 요법 |
| US20210155941A1 (en) | 2018-06-22 | 2021-05-27 | Kite Pharma Eu B.V. | Compositions and methods for making engineered t cells |
| EP3830125A1 (en) | 2018-08-02 | 2021-06-09 | Kite Pharma, Inc. | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
| EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| EP3632446B3 (en) | 2018-10-03 | 2024-01-24 | AVM Biotechnology, LLC | Immunoablative therapies |
| MX2021006968A (es) | 2018-12-12 | 2021-10-13 | Kite Pharma Inc | Antígeno quimérico y receptores de las células t, y métodos de uso. |
| WO2020208054A1 (en) | 2019-04-12 | 2020-10-15 | Cytovac A/S | Method for preparation of cancer/testis antigen-specific t-cells |
| CN118662516A (zh) | 2019-05-03 | 2024-09-20 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
| CN114391021A (zh) | 2019-06-21 | 2022-04-22 | 凯德药业股份有限公司 | TGF-β受体和使用方法 |
| WO2021046134A1 (en) | 2019-09-03 | 2021-03-11 | Allogene Therapeutics, Inc. | Methods of preparing t cells for t cell therapy |
| WO2021260675A1 (en) | 2020-06-24 | 2021-12-30 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
| IL299911A (en) | 2020-08-14 | 2023-03-01 | Kite Pharma Inc | Improving immune cell function |
| US12152251B2 (en) | 2020-08-25 | 2024-11-26 | Kite Pharma, Inc. | T cells with improved functionality |
| AU2021369507B2 (en) | 2020-10-28 | 2025-06-26 | Kite Pharma, Inc. | Flow cytometric method for characterization of t-cell impurities |
| CN116745319A (zh) | 2020-12-24 | 2023-09-12 | 凯德药业股份有限公司 | 前列腺癌嵌合抗原受体 |
| CA3207182A1 (en) | 2021-01-10 | 2022-07-14 | Kite Pharma, Inc. | T cell therapy |
| US20240076616A1 (en) | 2021-01-21 | 2024-03-07 | Cytovac A/S | Method for t-cell expansion and related medical applications |
| WO2022178243A1 (en) | 2021-02-20 | 2022-08-25 | Kite Pharma, Inc. | Gene markers for sellecting immunotherapies |
| IL305571A (en) | 2021-03-11 | 2023-10-01 | Kite Pharma Inc | Improving the function of immune system cells |
| US12337035B2 (en) | 2021-04-16 | 2025-06-24 | Kite Pharma, Inc. | TACI binding molecules |
| WO2022221126A1 (en) | 2021-04-16 | 2022-10-20 | Kite Pharma, Inc. | Methods and systems for scheduling a patient-specific immunotherapy procedure |
| AU2022274608B2 (en) | 2021-05-14 | 2025-12-11 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| KR20240013173A (ko) | 2021-05-24 | 2024-01-30 | 카이트 파마 인코포레이티드 | Nkg2d-기초 키메라 항원 수용체 |
| US20230020993A1 (en) | 2021-06-08 | 2023-01-19 | Kite Pharma, Inc. | Gpc3 binding molecules |
| WO2022269019A1 (en) | 2021-06-25 | 2022-12-29 | Cytovac A/S | Method for preparation of cytotoxic t lymphocytes with broad tumour-specific reactivity and characteristics of early differentiation cells |
| EP4363558A1 (en) | 2021-07-01 | 2024-05-08 | Kite Pharma, Inc. | Closed-system and method for autologous and allogeneic cell therapy manufacturing |
| JP2024525485A (ja) | 2021-07-02 | 2024-07-12 | カイト ファーマ インコーポレイテッド | 細胞療法適用において使用される遺伝子構築物由来の遺伝子産物におけるバリアントを特定するための方法 |
| US20230060292A1 (en) | 2021-07-26 | 2023-03-02 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
| KR20240027077A (ko) | 2021-07-30 | 2024-02-29 | 카이트 파마 인코포레이티드 | 세포 요법-유도 독성의 모니터링 및 관리 |
| EP4419559A1 (en) | 2021-10-18 | 2024-08-28 | Kite Pharma, Inc. | Signaling domains for chimeric antigen receptors |
| JP2025508376A (ja) | 2022-02-15 | 2025-03-26 | カイト ファーマ インコーポレイテッド | 免疫療法由来の有害事象の予測 |
| WO2023247324A1 (en) | 2022-06-24 | 2023-12-28 | Cytovac A/S | Novel combination treatment with adoptive cellular therapy |
| WO2024044670A1 (en) | 2022-08-26 | 2024-02-29 | Kite Pharma, Inc. | Improving immune cell function |
| AU2023367198A1 (en) | 2022-10-28 | 2025-04-17 | Kite Pharma, Inc. | Improving efficacy and durable response of immunotherapy |
| US20240158869A1 (en) | 2022-10-28 | 2024-05-16 | Kite Pharma, Inc. | Factors for optimizing immunotherapy |
| US20240309428A1 (en) | 2023-03-17 | 2024-09-19 | Kite Pharma, Inc. | Impact of tumor microenvironment on efficacy of immunotherapy |
| US20250161361A1 (en) | 2023-11-01 | 2025-05-22 | Kite Pharma, Inc. | Factors for optimizing immunotherapy efficacy |
| WO2025174963A1 (en) | 2024-02-16 | 2025-08-21 | Kite Pharma, Inc. | Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy |
| WO2025188561A1 (en) | 2024-03-04 | 2025-09-12 | Kite Pharma, Inc. | Predictive markers for immunotherapy |
| WO2025231376A1 (en) | 2024-05-03 | 2025-11-06 | Kite Pharma, Inc. | Chimeric receptors binding to cll-1 and methods of use thereof |
| US20250382383A1 (en) | 2024-05-31 | 2025-12-18 | Kite Pharma, Inc. | Tricistronic constructs for anti-gpc3 car |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
-
2007
- 2007-01-03 GB GBGB0700058.1A patent/GB0700058D0/en not_active Ceased
-
2008
- 2008-01-03 SI SI200830447T patent/SI2102331T1/sl unknown
- 2008-01-03 HR HR20110899T patent/HRP20110899T1/hr unknown
- 2008-01-03 JP JP2009544412A patent/JP5452231B2/ja not_active Expired - Fee Related
- 2008-01-03 PL PL08701232T patent/PL2102331T3/pl unknown
- 2008-01-03 AU AU2008203730A patent/AU2008203730B2/en not_active Ceased
- 2008-01-03 ES ES08701232T patent/ES2372713T3/es active Active
- 2008-01-03 PT PT08701232T patent/PT2102331E/pt unknown
- 2008-01-03 AT AT08701232T patent/ATE522600T1/de active
- 2008-01-03 WO PCT/EP2008/050050 patent/WO2008081035A1/en not_active Ceased
- 2008-01-03 US US12/522,048 patent/US10023839B2/en active Active
- 2008-01-03 DK DK08701232.4T patent/DK2102331T3/da active
- 2008-01-03 EP EP08701232A patent/EP2102331B1/en active Active
-
2011
- 2011-11-17 CY CY20111101112T patent/CY1112668T1/el unknown
-
2017
- 2017-09-18 US US15/707,474 patent/US20180036397A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514455A5 (cg-RX-API-DMAC7.html) | ||
| HRP20110899T1 (hr) | Protutumorsko cjepivo dobiveno iz normalnih, kemijski modificiranih stanica cd4+ | |
| Seledtsov et al. | Clinically feasible approaches to potentiating cancer cell-based immunotherapies | |
| JP6134763B2 (ja) | ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞 | |
| AU2003203051B2 (en) | Cancer therapy | |
| JP2015512866A5 (cg-RX-API-DMAC7.html) | ||
| JP2013535218A5 (cg-RX-API-DMAC7.html) | ||
| Taniguchi et al. | Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy | |
| JP2013177430A5 (cg-RX-API-DMAC7.html) | ||
| Ning et al. | β‐glucan restores tumor‐educated dendritic cell maturation to enhance antitumor immune responses | |
| JP2014514927A5 (cg-RX-API-DMAC7.html) | ||
| Liu et al. | Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK) | |
| JP2023539056A (ja) | Ｔ細胞を製造する組成物および方法 | |
| Huarte et al. | Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma | |
| JP2014533938A5 (cg-RX-API-DMAC7.html) | ||
| Choi et al. | The function of memory CD8+ T cells in immunotherapy for human diseases | |
| Yang et al. | Recent advances and challenges of cellular immunotherapies in lung cancer treatment | |
| Liseth et al. | Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience | |
| Gritzapis et al. | Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice | |
| Li et al. | Tumor cell-derived engineered exosome enhances effective immunotherapy for orthotopic glioblastoma and its recurrences | |
| Xu et al. | Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine | |
| Al Saihati | Overview of Dendritic Cell Vaccines as Effective Approaches in Cancer Immunotherapy. | |
| RU2016102172A (ru) | Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10 | |
| Delluc et al. | DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method | |
| Tripp et al. | Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells |